De-Escalating DAPT to Ticagrelor Monotherapy Cuts Bleeding Risk in Acute Coronary Syndrome
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Feb. 19, 2025 -- For patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation, de-escalating dual antiplatelet therapy (DAPT) to P2Y12 inhibitor monotherapy is associated with lower bleeding risk, without an increase in ischemic events, according to a review published online Feb. 18 in the Annals of Internal Medicine.
Yong-Joon Lee, M.D., from Severance Hospital at the Yonsei University College of Medicine in Seoul, South Korea, and colleagues compared the effects of de-escalating DAPT to ticagrelor monotherapy versus standard DAPT using data from randomized clinical trials involving patients with ACS. Individual patient data were obtained from three trials, including 9,130 randomized patients with ACS: 3,132 with ST-segment elevation myocardial infarction (STEMI); 3,023 with non-STEMI (NSTEMI); and 2,975 with unstable angina.
The researchers found no difference in the rate of the primary ischemic end point (composite of death, nonprocedural [spontaneous] myocardial infarction, or stroke) between the ticagrelor monotherapy and standard DAPT groups (1.7 versus 2.1 percent; hazard ratio, 0.85; 95 percent confidence interval, 0.63 to 1.16). The ticagrelor monotherapy group had a lower rate of the primary bleeding end point (0.8 versus 2.5 percent; hazard ratio, 0.30; 95 percent confidence interval, 0.21 to 0.45). The findings were consistent across STEMI, NSTEMI, and unstable angina.
"Our findings suggest that de-escalating DAPT to ticagrelor monotherapy will reduce aspirin-associated major bleeding while preserving the anti-ischemic benefits of antiplatelet therapy for patients with ACS of all types undergoing DES implantation," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
SARS-CoV-2 Infection Linked to More Rapid Plaque Growth in Lesions
MONDAY, Feb. 10, 2025 -- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with more rapid progression of coronary artery lesion-based plaque...
Primary Prevention Aspirin Use Decreased After Recommendation Change
FRIDAY, Jan. 24, 2025 -- Among older adults and adults with low atherosclerotic cardiovascular disease (ASCVD) risk for whom aspirin is not recommended, use of aspirin decreased...
Coronary Artery Disease Common in Patients With Cirrhosis
FRIDAY, Dec. 20, 2024 -- Coronary artery disease (CAD) is common in patients with cirrhosis, but cirrhosis itself is not significantly associated with an increased CAD risk...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.